Monitor upcoming FDA action on the cemdisiran application, expected within 10-12 months of submission. The combination of best-in-class efficacy, durable response, and convenient dosing could drive rapid adoption and premium pricing. Investors should also watch for updates on combination trials with pozelimab in PNH and geographic atrophy.
Price Chart
Executive Summary
Regeneron announced positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG), demonstrating statistically significant and clinically meaningful improvements in both primary and key secondary endpoints. The company has submitted a U.S. regulatory application and plans European filings in 2026, positioning cemdisiran as a potential first-in-class siRNA treatment for gMG with convenient quarterly dosing.
Key Facts
- Cemdisiran met primary endpoint with a 2.3-point placebo-adjusted improvement in MG-ADL score at week 24 (p<0.001)
- Achieved key secondary endpoint with a 2.8-point placebo-adjusted improvement in QMG score (p=0.002)
- 76.6% of cemdisiran patients had ≥3-point improvement in MG-ADL vs. 44.1% on placebo
- 48.4% of cemdisiran patients had ≥5-point improvement in QMG vs. 19% on placebo
- U.S. regulatory application submitted in Q1 2026; EU filings planned for 2026
- Cemdisiran is a novel siRNA therapeutic allowing for every-three-month subcutaneous dosing
Financial Impact
Potential blockbuster revenue opportunity; gMG affects ~85,000 people in the U.S. with high unmet need
Risk Factors
- Regulatory delay or rejection despite positive data
- Safety concerns related to complement inhibition (e.g., infection risk), particularly given the boxed warning for related drug Veopoz
- Competition from existing C5 inhibitors with established efficacy and safety profiles
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278163 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $781.49 | ▼ −7.35% | ▼ −6.20% | $735.20 (−12.84%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $799.08 | ▼ −3.55% | ▼ −4.02% | $735.20 (−11.26%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $807.71 | ▼ −2.29% | ▼ −3.40% | $735.20 (−11.06%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $840.84 | ▲ +5.37% | ▲ +5.81% | $735.20 (−7.87%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.57 | ▲ +1.33% | ▲ +1.73% | $735.20 (−7.75%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $772.11 | ▲ +4.57% | ▲ +0.95% | $735.20 (−0.43%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $772.11 | ▲ +4.57% | ▲ +0.95% | $735.20 (−0.43%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $759.24 | ▼ −9.21% | ▼ −6.95% | $735.20 (−5.76%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $651.91 | ▼ −3.66% | ▼ −2.97% | $735.20 (+8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access